Frauke Stascheit
Overview
Explore the profile of Frauke Stascheit including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
178
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Slioui A, Tammam G, Vanoli F, Marina A, Vohanka S, Gilhus N, et al.
Orphanet J Rare Dis
. 2025 Mar;
20(1):115.
PMID: 40069719
Background: Myasthenia gravis (MG) is a rare autoimmune disorder. Several new treatment concepts have emerged in recent years, but access to these treatments varies due to differing national reimbursement regulations,...
2.
Huntemann N, Gerischer L, Herdick M, Nelke C, Stascheit F, Hoffmann S, et al.
J Neurol Neurosurg Psychiatry
. 2025 Jan;
PMID: 39798960
Background: Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular junctions, leading to fluctuating muscle weakness. While many patients respond well to standard immunosuppression, a substantial subgroup faces ongoing disease...
3.
Stascheit F, de Sousa C, Aigner A, Behrens M, Keller C, Klotz L, et al.
Neurol Neuroimmunol Neuroinflamm
. 2024 Nov;
12(1):e200331.
PMID: 39602677
Background And Objectives: Biologics that target pathogenic antibodies (Abs) and their effector functions such as the complement inhibitor ravulizumab and the neonatal Fc receptor agonist efgartigimod have recently been approved...
4.
Hoffmann S, Holzer M, Preusse C, Ruck T, Ruffer N, Stascheit F, et al.
Nervenarzt
. 2024 Nov;
95(12):1181.
PMID: 39545977
No abstract available.
5.
Braun A, Shekhar S, Levey D, Straub P, Kraft J, Panagiotaropoulou G, et al.
Nat Commun
. 2024 Nov;
15(1):9839.
PMID: 39537604
Myasthenia gravis (MG) is a rare autoantibody-mediated disease affecting the neuromuscular junction. We performed a genome-wide association study of 5708 MG cases and 432,028 controls of European ancestry and a...
6.
Hoffmann S, Holzer M, Preusse C, Ruck T, Ruffer N, Stascheit F, et al.
Nervenarzt
. 2024 Sep;
95(10):920-931.
PMID: 39302417
This article deals with peripheral neuroimmunological diseases and briefly outlines the currently most important aspects and treatment developments. Idiopathic inflammatory myopathies have different mechanisms of development, manifestations and prognoses. New...
7.
Quint P, Schroeter C, Kohle F, Ozturk M, Meisel A, Tamburrino G, et al.
J Neurol
. 2024 Jul;
271(9):5930-5943.
PMID: 38990346
Background: Chronic inflammatory demyelinating polyneuropathy (CIDP) is an inflammatory disease affecting the peripheral nerves and the most frequent autoimmune polyneuropathy. Given the lack of established biomarkers or risk factors for...
8.
Nelke C, Schroeter C, Barman S, Stascheit F, Masanneck L, Theissen L, et al.
EBioMedicine
. 2024 Jul;
105:105231.
PMID: 38959848
Background: The clinical heterogeneity of myasthenia gravis (MG), an autoimmune disease defined by antibodies (Ab) directed against the postsynaptic membrane, constitutes a challenge for patient stratification and treatment decision making....
9.
Schroeter C, Nelke C, Stascheit F, Huntemann N, Preusse C, Dobelmann V, et al.
Acta Neuropathol
. 2024 Jun;
147(1):102.
PMID: 38888758
Myasthenia gravis is a chronic antibody-mediated autoimmune disease disrupting neuromuscular synaptic transmission. Informative biomarkers remain an unmet need to stratify patients with active disease requiring intensified monitoring and therapy; their...
10.
Chuquisana O, Stascheit F, Keller C, Pucic-Bakovic M, Patenaude A, Lauc G, et al.
Neurol Neuroimmunol Neuroinflamm
. 2024 Mar;
11(3):e200220.
PMID: 38507656
Background And Objectives: Antibodies (Abs) specific for the low-density lipoprotein receptor-related protein 4 (LRP4) occur in up to 5% of patients with myasthenia gravis (MG). The objective of this study...